Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
atyr1923 save search
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis
Published: 2022-08-11 (Crawled : 12:20) - globenewswire.com
LIFE | $1.59 -1.24% -1.26% 540K
|
Health Technology
|
| O: 1.07%
H: 2.65%
C: -3.18%
atyr1923 treatment fda designation pharma fast track designation
aTyr Pharma Presents Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
Published: 2022-05-17 (Crawled : 13:20) - biospace.com/
LIFE | $1.59 -1.24% -1.26% 540K
|
Health Technology
|
| O: 2.27%
H: 3.81%
C: 1.59%
atyr1923 pharma conference international
aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis
Published: 2022-05-16 (Crawled : 19:00) - biospace.com/
LIFE | $1.59 -1.24% -1.26% 540K
|
Health Technology
|
| O: 0.0%
H: 5.23%
C: 0.65%
atyr1923 pharma phase 3
aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod (ATYR1923) for Treatment of Systemic SclerosisSecond U.S. orphan drug designation for efzofitimod clinical program
Published: 2022-04-13 (Crawled : 17:00) - biospace.com/
LIFE | $1.59 -1.24% -1.26% 540K
|
Health Technology
|
| O: 0.21%
H: 10.73%
C: 7.16%
atyr1923 treatment fda pharma drug program designation
aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
Published: 2022-04-01 (Crawled : 20:00) - biospace.com/
LIFE | $1.59 -1.24% -1.26% 540K
|
Health Technology
|
| O: 4.67%
H: 6.61%
C: -0.18%
atyr1923 pharma conference international
aTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name
Published: 2022-01-13 (Crawled : 14:00) - biospace.com/
LIFE | $1.59 -1.24% -1.26% 540K
|
Health Technology
|
| O: -3.95%
H: 0.29%
C: -1.62%
atyr1923 announcement pharma
aTyr Pharma Announces FDA Orphan Drug Designation for ATYR1923 for Treatment of SarcoidosisCompany expects to initiate registrational trial of ATYR1923 in pulmonary sarcoidosis in 2022
Published: 2022-01-06 (Crawled : 15:30) - biospace.com/
LIFE | $1.59 -1.24% -1.26% 540K
|
Health Technology
|
| O: -1.1%
H: 2.78%
C: -0.56%
atyr1923 treatment fda drug trial orphan drug designation
aTyr Pharma and FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement for aTyr’s Lead Therapeutic Candidate ATYR1923
Published: 2021-11-30 (Crawled : 15:00) - biospace.com/
LIFE | $1.59 -1.24% -1.26% 540K
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
biotech iot pharma
aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Positive Data from a Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response of ATYR1923 in Pulmonary Sarcoidosis
Published: 2021-09-13 (Crawled : 12:00) - globenewswire.com
LIFE | $1.59 -1.24% -1.26% 540K
|
Health Technology
|
| O: 14.96%
H: 47.46%
C: 45.24%
biopharma phase 1 positive trial phase 1b phase 2b
aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis
Published: 2021-09-13 (Crawled : 12:00) - globenewswire.com
LIFE | $1.59 -1.24% -1.26% 540K
|
Health Technology
|
| O: 14.96%
H: 47.46%
C: 45.24%
phase 1 positive trial phase 1b phase 2b response
aTyr Pharma Announces Two Abstracts for ATYR1923 Accepted for Presentation at the European Respiratory Society International Congress
Published: 2021-08-09 (Crawled : 14:00) - biospace.com/
LIFE | $1.59 -1.24% -1.26% 540K
|
Health Technology
|
| O: 0.0%
H: 2.13%
C: 1.7%
presentation europe respiratory pharma
aTyr Pharma Announces Last Patient Visit in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis
Published: 2021-07-08 (Crawled : 14:15) - biospace.com/
LIFE | $1.59 -1.24% -1.26% 540K
|
Health Technology
|
| O: -1.75%
H: 4.91%
C: 4.46%
phase 1 trial phase 1b phase 2b
aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications
Published: 2021-03-15 (Crawled : 15:00) - biospace.com/
LIFE | $1.59 -1.24% -1.26% 540K
|
Health Technology
|
| O: 4.41%
H: 1.42%
C: -5.39%
covid phase 2 positive respiratory trial biomarkers
aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
Published: 2021-01-04 (Crawled : 22:00) - globenewswire.com
LIFE | $1.59 -1.24% -1.26% 540K
|
Health Technology
|
| O: 0.5%
H: 4.01%
C: -3.51%
covid positive results respiratory trial topline phase 2
aTyr Pharma Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis
Published: 2020-12-21 (Crawled : 12:03) - globenewswire.com
LIFE | $1.59 -1.24% -1.26% 540K
|
Health Technology
|
| O: 0.74%
H: 8.56%
C: 3.91%
trial phase 1b phase 2b enroll pharma
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.